ACARIX Acarix AB (publ)
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Acarix (STO: ACARIX)
›
Acarix (STO: ACARIX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 0.1540 SEK on 19 November 2026, down 46.0% over 52 weeks. Its 52-week range is 0.1412 SEK to 0.3445 SEK: the price is 55.3% below the high and 9.1% above the low.
Its market capitalisation is 191.04M SEK.
Acarix reports return on equity of -126.0%, an operating margin of -381.7% and revenue up 21.5% year over year.
It holds more cash than debt, a net cash position of 21.00M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.4000 SEK is 159.7% above the current price.